Jump to content
Search In
  • More options...
Find results that contain...
Find results in...
Sign in to follow this  
qwertyuiop

boomotherfuckinghoo

Recommended Posts

well, so much for not being depressed. my life sucks. im nowhere near getting laid, i have no friends, i have zits and braces, i dont fit in because im not one particular race, i havent been to a party since the eighth grade. ugh. feel sorry for me.

Share this post


Link to post
Share on other sites

on the bright side you have the ability to speak to us from the future. Anything happening tommorow I can win money on? help a brother out....

Share this post


Link to post
Share on other sites
Originally posted by ese

on the bright side you have the ability to speak to us from the future. Anything happening tommorow I can win money on? help a brother out....

 

ahhhhhhh.... hahahaha

Share this post


Link to post
Share on other sites
Guest MR BOJANGLES
Originally posted by qwertyuiop

oh, i forgot one, im at home on a saturday night typing on an internet message board instead of doing something cool.

well, if it makes you feel any better...im pretty cool and popular. and i chose to be on here too.:D

Share this post


Link to post
Share on other sites

Well, I think it's time for ol' Helacious D to hit the sack. Goodnight, sleep tight, everybody. Everybody, everywhere.......:dazed:

Share this post


Link to post
Share on other sites

We are using our platform to discover disease-associated proteins, and to date, we have filed patent applications relating to, or to the use of, several thousand proteins associated with important diseases. We are using these proteins to build a pipeline of proprietary drug candidates and proprietary diagnostic products. We expect our drug candidates to include small molecule compounds discovered through our glycochemistry expertise and fully human therapeutic monoclonal antibodies developed through our alliance with Medarex. Over the next three years, we intend to contribute to our Medarex alliance up to 30 disease-associated proteins that antibodies target, called antigens. Our goal is to submit our first investigational new drug, or IND, filing from this alliance within 12 months and multiple INDs each year thereafter. We expect our diagnostic products to be based on our discovery of proteins that can be used to assess and monitor disease, which are generally referred to as bio-markers.

 

 

In addition to our proteomics platform, we have extensive expertise in the field of carbohydrate biology known as glycobiology. This provides us with an additional source of protein targets for discovering drug candidates to treat such diseases as cancer, infectious disease, and glycolipid storage diseases. Our most advanced drug candidate, OGT 918, is a small molecule for the oral treatment of Gaucher's disease. OGT 918 is currently undergoing human clinical trials. Twelve-month trial data demonstrated statistically significant results in the primary objectives, or end-points, of reducing liver and spleen volume, as well as in the end-point of increasing platelets. Eighteen-month data on 18 patients that continued into an optional extension of the original trial, when compared with their data on entry into the trial, showed statistically significant reductions in liver and spleen volume, as well as statistically significant improvements in hemoglobin and platelets. OGT 918 has received 'fast track' designation by the U.S. FDA. We plan to file a new drug application, or NDA, for OGT 918 in 2001, subject to the successful completion of our preclinical and clinical development activities. We intend to develop a direct sales and marketing force to commercialise OGT 918 in some markets.

 

We were originally founded around a core glycobiology platform and have become a leader in the field of human glycobiology. Glycobiology is the study of the structure and functions of carbohydrates, the processes by which carbohydrates are formed and destroyed in the human body, and the biological processes in which they participate.

 

Our glycobiology background has given us an understanding of the processes in which carbohydrates are involved in human biology. We believe that the protein enzymes involved in the construction and break-down of carbohydrates (carbohydrate-processing enzymes, or CPEs) are an important class of targets for the discovery of new drugs for indications such as cancer, infectious disease and inflammation, as well as glycolipid storage diseases, such as Gaucher's disease, for which we are developing our leading product candidate, OGT 918. We have therefore continued to develop technologies for the analysis of carbohydrate structures, the isolation and cloning of CPEs, the design and implementation of highly selective high throughput screens for CPEs, and especially glycochemistry (the chemistries required to design carbohydrate analogs using combinatorial and medicinal chemistries).

 

We have focused our internal small-molecule drug discovery efforts against selected CPEs, for which we have established and conducted high throughput screens, using our internally designed, built and assembled chemical libraries. These screens have been successful in yielding inhibitors that are being developed into product candidates by our team of chemists.

Share this post


Link to post
Share on other sites

Register for a 12ozProphet forum account or sign in to comment

You need to be a forum member in order to comment. Forum accounts are separate from shop accounts.

Create an account

Register to become a 12ozProphet forum member.

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
Sign in to follow this  

×